United European Gastroenterology Week (UEGW) is the most prestigious international scientific conference in the field of clinical and experimental gastroenterology. Every year, the European GastroWeek brings together more than 14,000 participants from 120 countries. Due to the need to comply with quarantine requirements because of the COVID-19 pandemic, UEGW-2021 was held online on October 3-5, 2021, but the conference was attended by more than 8,000 professionals.
Scientific consultant of the Institute of Cell Therapy, Dr. Christina Nasadyuk, MD, PhD took part in UEGW-2021 and presented a report on the role of the purinergic signaling pathway in the stomach and colon in health and inflammatory conditions. The research was conducted in collaboration with Gdansk Medical University (Poland).
Digestive tract disorders are one of the leading diseases of the working age population in Ukraine and in the world, and colon cancer accounts for 9% of all newly detected malignant tumors. In the last decade, stem cells, in particular mesenchymal cells isolated from umbilical cord and placental tissue, have been increasingly used in the treatment of diseases of the digestive tract. In clinical trials, Crohn’s disease and ulcerative colitis are among the most common indications for cell therapy, particularly in cases resistant to traditional immunosuppressive therapy.
Today, the Institute of Cell Therapy in cooperation with leading state research institutes of the Academy of Medical Sciences of Ukraine develops approaches to the treatment of liver cirrhosis, viral hepatitis and inflammatory bowel disease using mesenchymal stem cells of the umbilical cord and placenta. The method of treatment of acute pancreatitis/pancreatic necrosis developed by the Institute of Cell Therapy using umbilical cord blood and umbilical cord stem cells in 2012 was officially approved by the Ministry of Health of Ukraine after 5 years of clinical trials.